Evidence map›Paper›PMID 40537241›Full record

ReviewJournal for immunotherapy of cancer2025

Reciprocal immune-epithelial interaction during breast cancer induction.

Neil Carleton, Michael T Lotze

Abstract readReview
In one paragraph

Review in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Neil CarletonWomen's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA carletonn2@upmc.edu.ORCID http://orcid.org/0000-0001-6985-7510
Michael T LotzeDepartments of Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID http://orcid.org/0000-0003-3988-5419

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Promotion of ER+ Breast Cancer Progression in the ElderlyF30CA264963 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARLETON, NEIL · 2021 to 2025
$243k
NCI NIH HHS F30 CA264963NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

The notion of immune editing and its defined phases (elimination, equilibrium, and escape), once a transformed cell emerges, is now well established. What occurs prior to, and may in fact impact, transformation-inflammation, initiation, and inception of malignancy-has been a murkier proposition. These "three I's" form the basis of a concept we put forth called reciprocal learning, which we define as a constant crosstalk in non-diseased tissue between the local epithelial cells and immune cells that occurs across the lifespan. Epithelial cells and resident macrophages provide the basis for genetic and epigenetic alterations as a site for learning by adaptive immune cells. Conversely, epithelial cells learn which changes are recognized by both innate and adaptive immune cells by modulating expression of MHC molecules and the antigen processing and presentation machinery. This "reciprocal learning" that occurs between the local epithelium and immune system provides memory for the immune system to then respond to dysregulated epithelial growth across the lifespan. We illustrate this with important recent findings of immune cells within the normal breast. An immune response is most certainly present (surveilling) the breast epithelium from the onset of mammary gland development, during active menstrual cycling, during lactation, and in the postmenopausal period with involution. We speculate that this reciprocal learning may be one of the main reasons why seven out of eight women

Indexed as

Breast NeoplasmsEpithelial CellsAnimalsFemaleHumansBreast CancerImmune modulatoryTumor microenvironment - TME

Identifiers

PMID40537241
PMCPMC12182196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.